Its secondary aim was to identify pretreatment markers in cerebral pain processing that might predict treatment response.<h4>Methods</h4>A total of 25 patients with RA were randomly allocated treatment with 40 mg ADA (n = 14) or placebo (PBO) (n = 11) injected subcutaneously. This evidence concerns the gene ADA and rheumatoid arthritis.